Search Medical Condition
Please enter condition
Please choose location from dropdown

Additional Locations, Minnesota Clinical Trials

A listing of Additional Locations, Minnesota clinical trials actively recruiting patient volunteers.

RESULTS

Found (1082) clinical trials

A Registry of Patients With Primary Choroidal Melanoma (CM) or Indeterminate Lesions (ILs)

This is a multi-center long-term observational Registry of patients with Primary Choroidal Melanoma (CM) or Indeterminate Lesions (ILs) The Registry will initially be open to patients who have previously participated in an Aura Biosciences sponsored clinical trial for their primary Choroidal Melanoma or Indeterminate Lesions. All patients will be followed ...

Phase N/A

1.24 miles

Learn More »

End-stage Renal Disease (ESRD) Pilot Study

The purpose of this study is to investigate the safety of two different doses of a drug called BAY1213790 and how well it is tolerated in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD). Approximately 40, with up to 60 study patients will take part in the study.

Phase

1.24 miles

Learn More »

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

This study will evaluate palbociclib in combination with chemotherapy (temozolomide and irinotecan) in children, adolescents and young adults with recurrent or refractory solid tumors. The main purpose of this study is to evaluate the safety of palbociclib in combination with chemotherapy in order to estimate the maximum tolerated dose. Pharmacokinetics ...

Phase

1.24 miles

Learn More »

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

Patients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial. The purpose of this trial is to determine a dose to select for a potential cardiovascular outcome trial with Ziltivekimab. Doses to be tested will be 7.5 mg, 15 ...

Phase

1.24 miles

Learn More »

Hydroxyurea Optimization Through Precision Study

The trial will recruit patients who have decided to initiate hydroxyurea therapy. All participants will have pharmacokinetics studies performed at baseline, following a 20 mg/kg oral dose of hydroxyurea. Pharmacokinetic sampling will use a sparse sampling approach, requiring collection of blood at 3 time points (15 minutes, 60 minutes, 180 ...

Phase

1.24 miles

Learn More »

Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa

This is a Phase 2, randomized, open-label study to evaluate efficacy and safety of oral vadadustat for the treatment of anemia in hemodialysis participants converting from epoetin alfa therapy. The study will be conducted in two parts running in parallel: Part 1, Main Study in a hemodialysis population on maintenance ...

Phase

1.24 miles

Learn More »

A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy

PRIMARY OBJECTIVES: I. To determine in a randomized manner if the addition of 2 cycles of blinatumomab to standard therapy improves disease-free survival (DFS) in patients with standard risk (SR) B-ALL and higher risk features (SR-High), and patients with standard-risk average (SR-Avg) B-ALL who are negative for minimal residual disease ...

Phase

1.24 miles

Learn More »

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

A study evaluating the effectiveness and safety of venetoclax, in combination with azacitidine or decitabine, in an outpatient setting for treatment-nave participants with AML who are ineligible for intensive chemotherapy.

Phase

1.24 miles

Learn More »

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

The purpose of this study is to evaluate the safety and tolerability of a 3-day intravenous (IV) fosaprepitant (MK-0517) regimen for the prevention of CINV in pediatric participants scheduled to receive emetogenic chemotherapy.

Phase

1.24 miles

Learn More »

Fabry Disease Registry

The Fabry Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact: In Asia-Pacific - Vivian Liu, +65-6431-2548, Vivian.liu@genzyme.com In Europe - +31-35-699-1232, europe@FabryRegistry.com In Latin America - +617-591-5500, help@FabryRegistry.com In North America - +617-591-5500, help@FabryRegistry.com

Phase N/A

1.24 miles

Learn More »